Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc., trading under ticker ARYB, emerged from the business combination of ARYA Sciences Acquisition Corp II and privately held Cerevel Therapeutics, a clinical-stage neuroscience biopharmaceutical company. ARYA Sciences Acquisition Corp II, sponsored by ARYA Sciences Management LLC, completed its IPO in 2020 and focused on healthcare and life sciences opportunities. The 10-Q filed November 16, 2020 represents one of the combined company's earliest public filings as a post-merger entity, with operations centered on developing treatments for neurological and psychiatric conditions including schizophrenia and Parkinson's disease. Sign up for full data on SpacDesk to access complete filing histories, deal timelines, and SPAC analytics across the healthcare sector and beyond.